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OBJECTIVE—Type 2 diabetes is characterized by diminished
pancreatic -cell mass and function. Insulin signaling within the
-cells has been shown to play a critical role in maintaining the
essential function of the -cells. Under basal conditions, en-
hanced insulin-PI3K signaling via deletion of phosphatase with
tensin homology (PTEN), a negative regulator of this pathway,
leads to increased -cell mass and function. In this study, we
investigated the effects of prolonged -cell–speciﬁc PTEN dele-
tion in models of type 2 diabetes.
RESEARCH DESIGN AND METHODS—Two models of type
2 diabetes were employed: a high-fat diet (HFD) model and a
db/db model that harbors a global leptin-signaling defect. A
Cre-loxP system driven by the rat insulin promoter (RIP) was
employed to obtain mice with -cell–speciﬁc PTEN deletion
(RIPcre
 Pten
ﬂ/ﬂ).
RESULTS—PTEN expression in islets was upregulated in both
models of type 2 diabetes. RIPcre
 Pten
ﬂ/ﬂ mice were completely
protected against diabetes in both models of type 2 diabetes. The
islets of RIPcre
 Pten
ﬂ/ﬂ mice already exhibited increased -cell
mass under basal conditions, and there was no further increase
under diabetic conditions. Their -cell function and islet PI3K
signaling remained intact, in contrast to HFD-fed wild-type and
db/db islets that exhibited diminished -cell function and atten-
uated PI3K signaling. These protective effects in -cells occurred
in the absence of compromised response to DNA-damaging
stimuli.
CONCLUSIONS—PTEN exerts a critical negative effect on
both -cell mass and function. Thus PTEN inhibition in -cells
can be a novel therapeutic intervention to prevent the decline
of -cell mass and function in type 2 diabetes. Diabetes 59:
3117–3126, 2010
T
he quintessential defects in type 2 diabetes are
the development of peripheral insulin resistance
and -cell dysfunction (1–3). In fact, the loss of
insulin secretion in -cells in response to glu-
cose occurs before the emergence of insulin resistance
and hyperglycemia (4–6). Once insulin resistance devel-
ops, hyperglycemia, high-circulating free fatty acids, and
inﬂammatory cytokines further abrogate glucose-stimu-
lated insulin secretion (2,7–9). It is becoming increasingly
clear that insulin/insulin-like growth factor 1 (IGF-1) sig-
naling plays an important role in the maintenance of -cell
function under both basal and diabetic conditions. Mice
with -cell–speciﬁc deletion of IGF-1 receptor exhibit a
defect in glucose-stimulated insulin secretion (10,11),
whereas insulin receptor deletion in -cells results in both
attenuated insulin secretion in response to glucose and
reduced -cell mass with aging (12,13). Thus, -cells are
not only an essential source of the hormone insulin, but
are also a critical target of insulin action in the mainte-
nance of -cell function.
Phosphoinositide 3-kinase (PI3K) signaling cascade is
one of the major intracellular signaling pathways through
which insulin and IGF-1 mediate their effects (14). Phos-
phatase with tensin homology (PTEN) is a dual-speciﬁc
phosphatase and a potent negative regulator of this path-
way by its ability to dephosphorylate phosphatidylinoso-
tol-3,4,5-triphosphate (PIP3) to phosphatidylinosotol-4,5-
bisphosphate (PIP2), thereby effectively removing the
critical secondary messenger of this signaling cascade
(15,16). Although PTEN was ﬁrst discovered as a tumor
suppressor, recent studies have highlighted the important
physiologic role of PTEN in metabolism (16–18). Tissue-
targeted deletion of PTEN in liver, fat, or muscle lead to
improved insulin sensitivity in these insulin-responsive
tissues and protects mice from HFD-induced diabetes
(19–22). Additionally, we and others have reported that
mice with PTEN deletion in pancreatic -cells show
increased -cell mass because of both increased prolifer-
ation and reduced apoptosis without compromising -cell
function under the basal condition (23,24).
PTEN has been shown to be upregulated in models of
insulin resistance, including a genetic model of combined
ablation of insulin/IGF-1 signaling in -cells (25–27). Fur-
thermore, in vitro overexpression of PTEN in pancreatic
-cell lines showed impaired insulin secretion in response
to ambient glucose (28). However, the regulation of PTEN
expression in -cells in models of type 2 diabetes in vivo
was unknown. We show here that PTEN expression was
increased in islets of both high-fat diet (HFD)-fed and
db/db mice, which was accompanied by attenuation in
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PTEN in the pathogenesis of -cell dysfunction in type 2
diabetes. In this report, we investigated the essential role
of PTEN in -cells in the context of type 2 diabetes
models. We used the rat insulin promoter (RIP) to drive
deletion of PTEN in the Cre-loxP system (RIPcre

Pten
ﬂ/ﬂ). RIPcre
 Pten
ﬂ/ﬂ mice were protected from HFD-
induced type 2 diabetes because of their increased islet
mass and proliferation with intact -cell function. -Cells
from RIPcre
 Pten
ﬂ/ﬂ mice were protected against HFD-
induced -cell dysfunction both in vitro and in vivo, which
can be attributed to the constitutively active PI3K signal-
ing in their islets. Furthermore, RIPcre
 Pten
ﬂ/ﬂ mice in
the db/db background still remained euglycemic, despite
being severely insulin resistant. Interestingly, their -cell
mass was not signiﬁcantly different from db/db littermates.
However, their -cell function and islet PI3K signaling
remained intact. Together, our data highlight the critical
role of -cell PTEN in the development of -cell dysfunc-
tion in type 2 diabetes and support PTEN as a potential
therapeutic target for -cell growth and the preservation
of its function.
RESEARCH DESIGN AND METHODS
Pten
ﬂ/ﬂ mice (exons 4 and 5 of Pten ﬂanked by loxP sites by homologous
recombination) were mated with RIPcre mice (Cre transgene under the
control of the rat insulin two promoter TgN[ins2-cre]25Mgn from Jackson
Laboratories). RIPcre
 Pten
/ﬂ mice were intercrossed to generate RIPcre

Pten
/, RIPcre
 Pten
/ﬂ, and RIPcre
 Pten
ﬂ/ﬂ mice. RIPcre
 Pten
/ mice
were used as controls. RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice were generated by
breeding RIPcre
 Pten
/ﬂ mice with Lepr
/db mice (Jackson Laboratories) to
obtain RIPcre
 Pten
/ﬂ Lepr
/db mice. RIPcre
 Pten
/ﬂ Lepr
/db mice were
then intercrossed to generate RIPcre
 Pten
/ Lepr
/ (wild-type), RIPcre

Pten
/ Lepr
db/db (db/db), and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db (/; db/db) mice.
Only male mice were used for experiments and only littermates were used as
controls. Genotypes for Cre and Pten gene were determined with PCR using
ear clip DNA as described previously (19,23). All mice were maintained on a
mixed 129J-C57BL/6 background and housed in a pathogen-free facility on a
12-h light-dark cycle and fed ad libitum with standard irradiated rodent chow
(5% fat; Harlan Tecklad, Indianapolis, IN) in accordance with the Ontario
Cancer Institute Animal Care Facility protocol, with no restrictions on the
animals’ activities.
High-fat diet feeding. HFD (Dyets lard Surmwit mouse diet DYET# 182084;
Fyets Inc., Bethlehem, PA) for RIPcre
 Pten
ﬂ/ﬂ and RIPcre
 Pten
/ mice was
started for mice at 2 months of age and continued for 7 months.
Metabolic studies. All overnight fasts were carried out between 5:00 P.M. and
10:00 A.M. All blood glucose, glucose tolerance tests, insulin tolerance tests,
and glucose-stimulated insulin secretion tests were performed on overnight-
fasted animals as previously described (23).
Islet perifusion assay. Detailed perifusion protocol was described in a
previous publication (29). In brief, 60 islets were placed in a perifusion
chamber at 37°C with a capacity of 1.3 ml, and perifused with Kreb-Ringer
bicarbonate buffer at 1 ml/min. Islets were equilibrated with Kreb-Ringer
bicarbonate HEPES buffer (2.8 mmol/l glucose) for 30 min. They were then
stimulated with 2.8 mmol/l glucose for 10 min, followed by a 40-min incuba-
tion with 16.7 mmol/l glucose. Fractional insulin content was determined with
radioimmunoassay kit (Linco Research, St. Louis, MO). At the end of each
perifusion, islets were collected and lysed with acid ethanol for assessment of
insulin content. First phase secretion was 10 to 25 min, and second phase
secretion was 25 to 50 min. Results were presented as insulin secreted
normalized to 60 islets and to total insulin content.
Immunohistochemistry and immunoﬂuorescence. Pancreas was ﬁxed in
4% paraformaldehyde in 0.1M PBS (pH 7.4) as previously described (25). For
immunohistochemical and immunoﬂuorescent staining antibodies against
PTEN (NeoMarker, Fremont, CA), Akt (Cell Signaling Technology, Beverly,
MA), p-Akt (Ser473) (Cell Signaling Technology, Beverly, MA), insulin
(DAKO), glucagon (NovoCastra Laboratories), laminin (Sigma), -catenin (BD
Transduction Laboratories), GLUT2 (Chemicon, Temecula, CA), PDX-1
(Chemicon, Temecula, CA), and Ki67 (DAKO) were used. Total islet area and
total pancreas area were determined on insulin immunohistochemically
stained sections with Image-Pro Plus software (Media Cybernetics, Silver
Spring, MD) and expressed as total islet area per total pancreas area.
Proportions of different islet sizes were measured on H&E-stained pancreas
sections: small (10 cells), medium (10–200 cells), and large (200 cells).
-Cell size was determined with insulin/DAPI costained pancreas sections.
Insulin-positive area was determined with Image-Pro Plus software (Media
Cybernetics, Silver Spring, MD) and divided by the number of DAPI-positive
nuclei within the insulin-stained areas.
Western blotting. Islets and hypothalami were isolated and protein lysates
were obtained as previously described (23). Antibodies against actin (Santa
Cruz Biotechnology, Santa Cruz, CA), Akt, p-Akt, FoxO-1 (Cell Signaling
Technology, Beverly, MA), p-FoxO-1 (Cell Signaling Technology, Beverly,
MA), GAPDH (Cell Signaling Technology, Beverly, MA), GLUT-2, mTOR
(Santa Cruz Biotechnology, Santa Cruz, CA), p-mTOR (Cell Signaling Tech-
nology, Beverly, MA), p-p53 (R&D systems), p53 (Santa Cruz Biotechnology,
Santa Cruz, CA), PDX-1, and PTEN were used (antibody sources for Akt,
p-Akt, GLUT-2, PDX-1, and PTEN refer to immunohistochemistry and
immunoﬂuorescence).
Gamma irradiation and quantitative PCR. Isolated islets are incubated in
RPMI-1640 (10% FBS) at 37°C overnight, then irradiated with 30Gy of gamma
irradiation the next day. Islets were harvested after overnight in culture. RNA
was extracted with RNeasy Plus Mini Kit (Qiagen, Valencia, CA) according to
protocol provided. Complimentary DNA was synthesized according to proto-
col published elsewhere (30). PCR was monitored in real time using the ABI
Prism 7900HT Real-Time PCR system (Applied Biosysterm). Experiments
were performed in triplicate for each sample. Primer sequences for Mdm2,
Bax, and p21 are available upon request.
Statistics. Data are presented as mean  SEM and were analyzed by
one-sample t test, independent-sample t test, and one-way ANOVA with the
post hoc Tukey least signiﬁcant difference test, when appropriate. All data
were analyzed using the statistical software package SPSS (version 16.0) for
Macintosh.
RESULTS
Increased PTEN expression with attenuated PI3K
signaling in islets of HFD-fed and db/db mice. PTEN
transcript and protein levels were measured in islets of
mice with type 2 diabetes. In both HFD-induced and db/db
mice, PTEN transcripts in islets were signiﬁcantly in-
creased as accessed by quantitative real-time PCR (Fig.
1A). PTEN protein expression was also increased as
demonstrated by immunohistochemistry of pancreatic
sections and Western blotting of isolated islet lysates (Fig.
1B and C). The increase in islet PTEN expression in both
of these type 2 diabetes models was accompanied by
attenuated PI3K signaling, as demonstrated by the reduc-
tion of p-Akt, p-mTOR, and p-FoxO-1 expression (Fig. 1C).
RIPcre
 Pten
ﬂ/ﬂ mice were protected against HFD-
induced diabetes. We have previously shown that
RIPcre
 Pten
ﬂ/ﬂ mice exhibit an increase in -cell mass
and function under basal conditions (23). To investigate
whether these positive attributes of PTEN deletion in
pancreatic -cells conferred protection against type 2
diabetes, we fed these mice a prolonged HFD for 7
months. Efﬁcient PTEN deletion in -cells, along with
partial deletion in the hypothalamus, persisted in the
RIPcre
 Pten
ﬂ/ﬂ mice on prolonged HFD (Fig. 2A and B).
Despite their increased weight gain upon HFD feeding,
RIPcre
 Pten
ﬂ/ﬂ mice remained remarkably euglycemic
throughout the duration of prolonged HFD, in contrast to
the gradual increase in blood glucose levels in control
littermates (Fig. 3A and B). They also exhibited improved
glucose tolerance (Fig. 3C). The attenuation of insulin
secretion in response to glucose is a characteristic -cell
defect in type 2 diabetes (1–3). Indeed, this attenuation
was observed in both the ﬁrst and second phases of insulin
secretion after in vivo glucose challenge in wild-type mice
after a prolonged HFD. In contrast, insulin secretion in
response to glucose was preserved in RIPcre
 Pten
ﬂ/ﬂ
mice (Fig. 3D).
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HFD-fed RIPcre
 Pten
ﬂ/ﬂ mice. During HFD-induced
diabetes, development of peripheral insulin resistance
leads to a compensatory increase in -cell mass to meet
the increasing demands for insulin. This compensatory
proliferation was observed in RIPcre
 Pten
/ islets on
HFD (Fig. 4A and B). RIPcre
 Pten
ﬂ/ﬂ islets showed an
already increased -cell mass under chow-fed conditions,
and we observed no further increase in -cell mass in the
mice on HFD. The increased -cell mass was due to both
an increase in proliferation and -cell size in RIPcre

Pten
ﬂ/ﬂ mice under both chow and HFD conditions, which
likely reﬂects the direct effects of PTEN deletion in their
-cells (Fig. 4C, E, and F). Furthermore, age-matched
chow- and HFD-fed RIPcre
 Pten
ﬂ/ﬂ mice showed similarly
increased proportion of large islets (Fig. 4D). Despite the
increased proliferation and cellular growth in RIPcre

Pten
ﬂ/ﬂ islets, their architectures were maintained (Fig.
5A).
RIPcre
 Pten
ﬂ/ﬂ islets were protected against HFD-
induced -cell dysfunction. In order to assess the direct
effects of PTEN deletion speciﬁcally in -cells, we mea-
sured insulin secretion during perifusion assay on isolated
islets ex vivo. Under basal condition, both RIPcre

Pten
/ and RIPcre
 Pten
ﬂ/ﬂ islets demonstrated similar
insulin release after glucose stimulation (Fig. 4G and H).
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FIG. 1. Islet PTEN upregulation with concomitant attenuation of PI3K signaling in models of type 2 diabetes. A and B: PTEN transcript levels by
quantitative PCR (A) and immunohistochemical staining (B) of chow- and HFD-fed (after 7 months on HFD); wild-type (/) and db/db islets
(7 months of age) (n  3). C: Western blot (left panel) and quantiﬁcation (right panel) of PTEN, p-Akt (Ser473), total Akt, p-mTOR (Ser2448),
total mTOR, p-FoxO-1 (Ser253) and total FoxO-1 in chow- and HFD-fed (7 months on HFD); wild-type and db/db islets (7 months of age) (n 
3). *P < 0.05; **P < 0.005. Scale bar, 50 m. The results are presented as mean  SE. (A high-quality digital representation of this ﬁgure is
available in the online issue.)
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FIG. 2. PTEN deletion in RIPcre
 Pten
ﬂ/ﬂ islets. A: Immunohistochemical staining of PTEN in RIPcre
 Pten
/ (/) and RIPcre
 Pten
ﬂ/ﬂ (/)
pancreas sections. B: Western blot (left panel) and quantiﬁcation (right panel) of PTEN expression in RIPcre
 Pten
ﬂ/ﬂ islets and hypothalamus
(Hyp) (n  3). *P < 0.05; **P < 0.005. Scale bar, 50 m. The results are presented as mean  SE. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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 Pten
ﬂ/ﬂ mice main-
tained robust insulin secretion in response to glucose in
contrast to islets of HFD-fed RIPcre
 Pten
/ mice, which
showed attenuation in both phases of insulin secretion
(Fig. 4I and J). These data suggest that diabetes protection
in HFD-fed RIPcre
 Pten
ﬂ/ﬂ mice are likely due to both
preserved -cell function and mass.
Maintained high PI3K signaling in RIPcre
 Pten
ﬂ/ﬂ
islets after prolonged HFD. To determine the mecha-
nisms underlying the enhanced -cell growth and main-
tained function after HFD feeding in islets of RIPcre

Pten
ﬂ/ﬂ mice, we assessed for alterations in the PI3K
signaling pathway. HFD has been shown to attenuate
phosphorylation of Akt in -cells (7). However this decline
was not observed in PTEN-deﬁcient islets, which indicates
persistent activation of the PI3K pathway even after pro-
longed exposure to HFD (Fig. 5A and B). FoxO-1 and
mTOR, both downstream effectors of PI3K signaling,
showed increased phosphorylation in HFD-fed RIPcre

Pten
ﬂ/ﬂ islets (Fig. 5B). The increased p-mTOR was in
keeping with the increased -cell size in RIPcre
 Pten
ﬂ/ﬂ
mice (Fig. 4E and F). The expression of GLUT-2, a marker
of -cell differentiation and a rate-limiting component in
glucose sensing, has also been shown to decline with the
progression of type 2 diabetes (31,32). GLUT2 remained
high in HFD-fed RIPcre
 Pten
ﬂ/ﬂ islets to a similar degree
as the islets of chow-fed RIPcre
 Pten
/ mice, in contrast
with the decline of GLUT2 in islets of HFD-fed RIPcre

Pten
/ mice (Fig. 5A and B). Furthermore, PDX-1, a
downstream transcriptional target of insulin signaling im-
portant in -cell differentiation and growth (33), was also
increased in RIPcre
 Pten
ﬂ/ﬂ islets, which may also con-
tribute to the preserved -cell mass and function in
HFD-fed RIPcre
 Pten
ﬂ/ﬂ mice (Fig. 5A and B). However,
RIPcre
 Pten
ﬂ/ﬂ mice also exhibited increased peripheral
insulin sensitivity because of partial neuronal deletion of
PTEN (L.W. and M.W., unpublished data). To circumvent
the potential confounding effects of enhanced insulin
sensitivity, we next examined RIPcre
 Pten
ﬂ/ﬂ mice in a
db/db model of type 2 diabetes which did develop insulin
resistance as described below.
RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice remained euglycemic
despite severe insulin resistance. Both RIPcre
 Pten
ﬂ/ﬂ
Lepr
db/db mice and RIPcre
 Pten
/ Lepr
db/db littermates
exhibited similar degrees of weight gain and insulin resis-
tance (Fig. 6A and D). However, despite severe insulin
resistance in RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice, they contin-
ued to remain remarkably euglycemic and showed normal
glucose tolerance (Fig. 6B and C). Furthermore, in vivo
GSIS experiments showed robust insulin secretion in
response to glucose stimulation in RIPcre
 Pten
ﬂ/ﬂ
Lepr
db/db mice (Fig. 6E). Interestingly, islets of RIPcre

Pten
ﬂ/ﬂ Lepr
db/db mice demonstrated similar degrees of
hypertrophy and proliferation as those of RIPcre
 Pten
/
Lepr
db/db islets and did not show a further increase in
-cell mass compared with db/db controls (Fig. 7B and C).
Islets of RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice showed no signs of
disorganized architecture (Fig. 7A).
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FIG. 3. RIPcre
 Pten
ﬂ/ﬂ mice showed maintained glucose metabolism and in vivo glucose stimulated insulin secretion after prolonged HFD while
demonstrating drastic weight gain. A: Weight of RIPcre
 Pten
/ (/) and RIPcre
 Pten
ﬂ/ﬂ (/) mice at the start of HFD (2 months of age) and
after HFD (9 months of age) with chow-fed RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ mice at the same time points. B: Fasting blood glucose of RIPcre

Pten
/ and RIPcre
 Pten
ﬂ/ﬂ mice fed either chow or HFD for 7 months (n >7). C: Glucose tolerance tests of RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ
mice after 7 months of either chow or HFD feeding (n >7). D: in vivo glucose stimulated insulin secretions of RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ
mice after 7 months of either chow or HFD feeding (n >3). *P < 0.05. The results are presented as mean  SE.
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 Pten
ﬂ/ﬂ Lepr
db/db islets demonstrated in-
creased -cell function. To assess the direct effects of
PTEN deletion on -cell function in the absence of leptin
signaling, we examined islet function ex vivo by perifu-
sion. RIPcre
 Pten
/ Lepr
db/db islets showed diminished
insulin secretion, whereas robust ﬁrst phase insulin secre-
tion was observed in RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db islets after
glucose stimulation, further conﬁrming the preserved glu-
cose-responsive insulin secretory function in PTEN-deﬁ-
cient -cells in db/db mice (Fig. 6F and G). Thus, in
contrast to the HFD-fed RIPcre
 Pten
ﬂ/ﬂ mice, where the
combination of increased -cell mass and function likely
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FIG. 4. RIPcre
 Pten
ﬂ/ﬂ mice maintained high islet mass and -cell size with protection against HFD-induced -cell dysfunction. A and B: Insulin
staining (A) and quantiﬁcation (B) of pancreas sections of RIPcre
 Pten
/ (/) and RIPcre
 Pten
ﬂ/ﬂ (/) mice fed either chow or HFD (n 
3), Scale bar, 500 m. C: Percentage of Ki67 positive cells in islets from RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ mice fed either chow or HFD (n 
3). D: proportion of small (<10 cells), medium (10–200 cells) and large (>200 cells) islet in pancreas from RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ
mice fed either chow or HFD (n  3). E and F: Immunoﬂuorescent staining of insulin/DAPI (E) and quantiﬁcation of -cell size (F) of pancreas
from RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ mice fed either chow or HFD (n  3), Scale bar, 50 m. G and H: Insulin secretion per 60 islets during
perifusion analysis (G) and quantiﬁcation of area under the curve (AUC) (H) of chow-fed RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ islets (n  3).
I and J: Insulin secretion per 60 islets during perifusion analysis (I) and quantiﬁcation of area under the curve (J) of HFD-fed RIPcre
 Pten
/
and RIPcre
 Pten
ﬂ/ﬂ islets (n  3). *P < 0.05. Results are presented as mean  SE. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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creased -cell function and not mass in RIPcre
 Pten
ﬂ/ﬂ
Lepr
db/db mice was likely responsible for their diabetes
protection.
Enhanced PI3K signaling in RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db
islets. We next determined the effects of PTEN deletion
on PI3K signaling in -cells in the db/db model. RIPcre

Pten
/ Lepr
db/db islets showed reduced levels of p-Akt,
whereas PTEN deletion completely rescued this defect
(Fig. 7A and D). Phosphorylation of mTOR and FoxO-1
also remained high in RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db islets,
consistent with constitutively active PI3K cascade (Fig.
7D). In keeping with its normal insulin secretion in re-
sponse to glucose, GLUT2 was highly expressed in islets of
RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice in contrast to the near-
complete loss of GLUT2 expression in islets of Lepr
db/db
mice (Fig. 7A and D). PDX-1 was also downregulated in
RIPcre
 Pten
/ Lepr
db/db islets, whereas the RIPcre

Pten
ﬂ/ﬂ Lepr
db/db islets continued to show intense expres-
sion of PDX-1 and nuclear localization of the protein to a
similar degree as the wild-type islets on chow diet (Fig. 7A
and D).
Tumorigenic response to DNA-damaging stimuli is
not compromised in islets of RIPcre
 Pten
ﬂ/ﬂ or
RIPcre

Pten
ﬂ/ﬂ Lepr
db/db mice. Given PTENs role as a
tumor suppressor in various cancer-prone tissues (16–18),
we assessed for changes suggestive of cellular transforma-
tion and response to DNA-damaging stimuli such as
gamma irradiation. Despite the signiﬁcant increase in islet
mass in both HFD-fed RIPcre
 Pten
ﬂ/ﬂ and RIPcre
 Pten
ﬂ/ﬂ
Lepr
db/db islets, intact islet integrity was observed even in
the 9-month-old aged mice fed either HFD or on db/db
background. Intact laminin staining in the basement mem-
brane as well as localization of -catenin to the plasma
membrane both demonstrated absence of deregulated
growth (Fig. 8A). Furthermore, induction of DNA damage
with gamma irradiation showed a similar degree of DNA-
repair and apoptosis response in both RIPcre
 Pten
/
and RIPcre
 Pten
ﬂ/ﬂ islets, including phosphorylation of
p53 and cleavage of MDM2 (Fig. 8C). The transcript levels
of p53 target genes, including Bax, Mdm2, and p21 also
showed similar changes in response to gamma irradiation
between RIPcre
 Pten
/ and RIPcre
 Pten
ﬂ/ﬂ islets (Fig.
8B). Interestingly RIPcre
 Pten
ﬂ/ﬂ islets exhibited signiﬁ-
cantly reduced expression of proapoptotic gene Bax under
basal condition, which is consistent with their constitu-
tively active PI3K signaling (Fig. 8B). Thus, PTEN deletion
in -cells protects against -cell dysfunction in both HFD
and db/db models of type 2 diabetes with no ﬁnding
suggestive of deregulated growth. Furthermore, PTEN-
deleted -cells still maintained intact response to DNA-
damaging stimuli, which further suggests that they are not
more prone to tumor formation.
DISCUSSION
In pre-diabetic individuals, insulin resistance in the classic
metabolic tissues including the liver, muscle, and fat is
present; however, glucose homeostasis can be maintained
as long as pancreatic -cells are able to increase insulin
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 Pten
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
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 Pten
/ and RIPcre
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ﬂ/ﬂ mice fed either chow or HFD (n  3).
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(7,34,35). Accumulating evidence shows that a defect in
insulin-PI3K signaling in pancreatic -cells may contribute
to the development of -cell dysfunction, leading to the
onset of type 2 diabetes. Indeed, mice with genetic abla-
tion of insulin/IGF-1 receptors speciﬁcally in the -cells
demonstrate reduced -cell function (10,12,13). Therefore,
a new paradigm of type 2 diabetes pathogenesis suggests
that diminished insulin responsiveness speciﬁcally in the
pancreatic -cells plays a central role in disease
development.
Interestingly, PTEN, a critical negative regulator of the
PI3K signaling pathway, has been shown to be upregulated
in -cells that have complete absence of insulin/IGF-1
signaling (25), leading to a hypothesis that PTEN may play
a causal role in the pathogenesis of -cell dysfunction.
Here we have shown that when type 2 diabetes was
induced, either by HFD or global leptin signaling deﬁ-
ciency, increased PTEN expression was observed in islets
along with diminished PI3K signaling, suggesting that
-cell PTEN may indeed play a critical role in the devel-
opment of type 2 diabetes. We and others have already
shown that tissue-speciﬁc increase in PI3K signaling in
pancreatic -cells resulting from deletion of PTEN leads to
increased -cell mass and function under basal conditions
(23,24). However, the biologic outcome from continued
deletion of PTEN in -cells under metabolically stressed
conditions was elusive. In this report, we show that after
prolonged HFD, RIPcre
 Pten
ﬂ/ﬂ mice continued to exhibit
increased islet mass and were protected against the loss of
glucose-stimulation insulin secretion. The enhanced -cell
function was demonstrated not only in vivo, but also in
vitro, which supports the direct effect of PTEN in -cells.
However, RIPcre
 Pten
ﬂ/ﬂ mice exhibited enhanced insu-
lin sensitivity, which may have masked the full potential
effects of PTEN deletion in pancreatic -cells against
metabolic stress in the HFD model.
In the db/db model, RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice
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FIG. 6. RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice exhibited comparable weight gain and normal glucose tolerance despite being insulin resistant with normal
-cell function. A: Weight of wild-type (WT), RIPcre
 Pten
/ Lepr
db/db (db/db), and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db (/; db/db) mice at 2 and 7
months of age (n >7). B: Fed blood glucose of wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice from 2 to 7 months of age
(n >7). C: Glucose tolerance test of wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice at 7 months of age (n >7). D: Insulin
tolerance test of wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice at 7 months of age (n >7). E: In vivo glucose-stimulated
insulin secretion of wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice at 7 months of age (n  3). F and G: Insulin secretion
per 60 islets during perifusion analysis (F) and quantiﬁcation of area under the curve (G) of wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre

Pten
ﬂ/ﬂ Lepr
db/db mice (n  3). *P < 0.05 for RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice compared with RIPcre
 Pten
/ Lepr
db/db mice or as indicated; P <
0.05 for both RIPcre
 Pten
/ Lepr
db/db and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice compared with wild-type mice. Results are presented as mean  SE.
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sensitivity to a similar degree as the RIPcre
 Pten
/
Lepr
db/db littermate controls (Fig. 6A and D). Yet, RIPcre

Pten
ﬂ/ﬂ Lepr
db/db mice remained completely glucose toler-
ant and euglycemic throughout the 7-month period. Islets
from RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice demonstrated an
increase in islet area to a similar degree as those of
RIPcre
 Pten
/ Lepr
db/db mice. However RIPcre
 Pten
ﬂ/ﬂ
Lepr
db/db islets remained responsive to glucose-stimulated
insulin secretion. This is likely attributed by the PI3K
signaling which remained activated in these islets. As such
GLUT-2 and PDX-1, which are important in glucose sens-
ing and cell differentiation, are maintained. These data
illustrate the importance of the negative regulation that
PTEN exerts on -cells, whereupon PTEN deletion leads
to enhanced PI3K signaling and protection against -cell
dysfunction that occurs in type 2 diabetes.
Given the well known tumorigenic effects of PTEN
deletion in some tissues, we assessed for evidence of
deregulated growth (16–18). PTEN deﬁcient islets showed
intact architecture and demonstrated intact DNA repair
response to gamma irradiation as wild-type counterparts.
Furthermore, previously we have shown that PTEN dele-
tion in combination with the activation of the cMyc
oncogene is still not able to lead to tumor formation (36).
However, more extensive analysis and longitudinal obser-
vation are required to conclusively demonstrate the full
impact of PTEN deletion in pancreatic -cells on tumori-
genesis. It is worth noting that PTEN-deleted -cells
behave differently than -cells that express constitutively
active Akt. Although the RIP-Akt transgenic mice exhibit
increased islet mass, these mice have compromised -cell
function (37,38). PTEN-deﬁcient -cells, in contrast, do
not show loss of function even after a prolonged exposure
to HFD, despite the continued proliferation and PI3K
signaling within these cells. This important distinction
between PTEN-deleted and Akt-overexpressing -cells il-
lustrates the fundamental difference between removing a
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FIG. 7. RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice exhibit islet hypertrophy with normal islet architecture and enhanced PI3K signaling. A: Immunoﬂuores-
cent staining of insulin/glucagon, and immunohistochemical staining of synaptophysin, p-Akt (Ser473), total Akt, GLUT2, and PDX-1 in wild-type
(WT), RIPcre
 Pten
/ Lepr
db/db (db/db), and RIPcre
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ﬂ/ﬂ Lepr
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db/db at 7 months of age (n  4). C: Percentage of Ki67 positive cells in wild-type,
RIPcre
 Pten
/ Lepr
db/db, and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice at 7 months of age (n  4). D: Western blot (left panel) and quantiﬁcation (right
panel) of p-Akt (Ser473), total Akt, p-mTOR (Ser2448), total mTOR, p-FoxO-1 (Ser253), total FoxO-1, GLUT-2, and PDX-1 of islets from
wild-type, RIPcre
 Pten
/ Lepr
db/db, and RIPcre
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ﬂ/ﬂ Lepr
db/db mice at 7 months of age (n  3). *P < 0.05. Scale bar, 500 m( A, top panel);
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return to physiologic levels, whereas forced expression of
Akt may lead to supraphysiologic levels of PI3K signaling
that can lead to cell proliferation and dedifferentiation.
Further investigations to delineate other important genes
or pathways that distinguish between these two modes of
enhancing PI3K signaling may unveil clinically safe thera-
peutic targets for -cells.
In summary, our ﬁndings show that PTEN plays a
critical role in the pathogenesis of -cell dysfunction in
type 2 diabetes and highlight the tissue-speciﬁc role of
PTEN in attenuating PI3K signaling in -cells. Our results
show that PTEN deletion in -cells leads to an increase in
-cell mass and function as a result of restoring PI3K
signaling to a physiologic level in diabetic condition.
Indeed, PTEN deletion leads to complete protection
against -cell defects even in the face of severe insulin
resistance, providing genetic evidence of the critical neg-
ative regulation that PTEN exerts in impeding -cell
function and growth that occurs in type 2 diabetes. Our
results highlight opportunities for therapeutic targeting of
PTEN in -cells for treatment or prevention of type 2
diabetes.
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FIG. 8. HFD-fed RIPcre
 Pten
ﬂ/ﬂ and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db mice showed intact islet integrity and uncompromised response to gamma
irradiation. A: Laminin and -catenin staining demonstrated intact basement membrane and cell-to-cell adhesion in HFD-fed (9 months of age)
RIPcre
 Pten
ﬂ/ﬂ (/) and RIPcre
 Pten
ﬂ/ﬂ Lepr
db/db (/; db/db) (9 months of age) mice. B: Transcripts levels of p53-related gene including Bax,
Mdm2, and p21 during quantitative PCR of RIPcre
 Pten
/ (/) and RIPcre
 Pten
ﬂ/ﬂ islets with or without 30Gy gamma irradiation (n  2).
C: Western blotting (left panel) and quantiﬁcation (right panel) of p-p53 (Ser392), total p53, cleaved MDM2, and total MDM2 in RIPcre
 Pten
/
and RIPcre
 Pten
ﬂ/ﬂ islets with or without 30Gy gamma irradiation (n  2). *P < 0.05. Scale bar, 50 m. Results are presented as mean  SE. (A
high-quality digital representation of this ﬁgure is available in the online issue.)
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